Year: 2017
Value-focused Drug Development Strategies of the Future
Mounting healthcare and R&D costs, high drug attrition rates leading to decreased numbers of new molecular entity approvals, and growing demands from regulators and payers indicate that a paradigm shift is needed to improve efficiency and productivity across the drug development continuum.
Certara-Monash University Industry Fellowship Program Receives Funding from MTPConnect
MELBOURNE, AUSTRALIA – 2017年10月26日 – MTPConnect today announced it will provide provisional funding to the Certara-Monash University Industry Fellowship Program over two years, with proposed matched funding coming from Certara.
Use of a PBPK Modeling Approach to Predict the In Vivo Clearance of Aldehyde Oxidase Substrates
An Integrated PBPK/PD Feedback Model to Predict Drug-drug Interactions Between Gastric Acid Reducing Agents and Drugs with pH Dependent Solubility
Simulation Re-estimation and Bayesian Optimal Design for Population Pharmacokinetic Studies
An R-shiny Web Application to Support Early Assessment and Decision-making of Oncology Studies Using Multivariate Tumor Growth Inhibition and Overall Survival Disease Models
Implementation of Distributed Delays for Absorption Delays and Delayed Drug Response
Certara to Participate in 27 Pharmacometrics Modeling and Simulation and Meta-analysis Sessions at ACoP8
PRINCETON, NJ – Oct. 13, 2017 – Certara today announced that it is participating in 27 sessions at the eighth American Conference on Pharmacometrics (ACoP8).
Pharmacology to Payer: Quantitative Drug Development Framework to Rule Them All
Watch this webinar with Drs. Carl Kirkpatrick and Craig Rayner to learn how “pharmacology to payer” (P2P) can be used as a quantitative framework that bridges the disciplines of pharmacology, epidemiology, and health economics to support meaningful dialogue between industry, regulators, and payers.
